Back to 2025 Abstracts
Ibuprofen Is Not Associated With An Elevated Bleeding Risk Or Transfusion Requirement In Skin Grafting In Patients With Burn Injuries
Artur Manasyan, BS, Jordan Gasho, BS, Michael Kim, BS, Eloise Stanton, MD, Maxwell Johnson, MD, Haig A. Yenikomshian, MD, justin gillenwater, MD.
Keck School of Medicine, Los Angeles, CA, USA.
PURPOSE: Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), increasingly used alongside other medications to manage pain, reducing reliance on opioids. However, it can increase the risk of bleeding, a significant concern in burn surgery, which often involves substantial blood loss. This study aims to evaluate the safety of ibuprofen use in burn patients undergoing skin grafting.
METHODS: A retrospective case-control chart review was conducted for patients admitted with acute burn injury from 01/01/2024 to 07/31/2024 who underwent skin grafting. The primary outcome variables included perioperative transfusion requirement, bleeding, skin graft failure, and other complications.
RESULTS: A total of 53 patients met inclusion criteria, 24 (45.2%) of whom received scheduled ibuprofen therapy during their hospitalization. The total body surface area affected was 12.3±9.3% for the non-ibuprofen group and 14.3±12.1% for the ibuprofen group (p=0.62). Perioperative transfusion requirements were similar between the two cohorts, averaging 4.6±3.1 for the non-ibuprofen group and 3.2±2.8 units of packed red blood cells for the ibuprofen group (p=0.207). Skin graft failure (defined as need for re-grafting) occurred in 6.9% (n=2) of the non-ibuprofen cohort versus none (n=0) in the ibuprofen group (p=0.112). Postoperative complications did not vary significantly between the two groups for seroma (p=0.259) and infection (p=0.568). There were no cases of hypersensitivity or gastrointestinal bleeding.
CONCLUSION: There is likely no increased risk of bleeding or skin graft failure in burn injury patients taking ibuprofen, suggesting that these medications may be safe in this context.
Back to 2025 Abstracts
